Who we are

Across all four sites, our leading neurologists have a neuroimmunological focus and are embedded in strong neuroscientific and immunological communities.  In addition, each site makes its own specific contributions to the initiative.  Leading the research at each of these sites are:

  • Rhine-Main Neuroscience Network: Stefan Bittner, Tobias Bopp, Erik Ellwardt, Vinzenz Fleischer, Sergiu Groppa, Claire Jacob, Felix Lüssi, Muthuraman Muthuraman, Detlef Schuppan, Albrecht Stroh, Timo Uphaus, Christina Vogelaar, Ari Waisman and Frauke Zipp
  • Munich neuroimmunologists: Naoto Kawakami, Martin Kerschensteiner, Thomas Korn, Tanja Kümpfel, Klaus Lehmann-Horn, Edgar Meinl, Anneli Peters, Mikael Simons
  • Münster Center: Thomas Budde, Kerstin Göbel, Catharina Groß, Luisa Klotz, Tanja Kuhlmann, Jan Lünemann, Gerd Meyer zu Hörste, Nicholas Schwab, Lydia Sorokin, Heinz Wiendl and Alexander Zarbock
  • Bochum Center: Ralf Gold

Associated Members

  • Aiden Haghikia (Magdeburg), Karin Loser (Oldenburg), Sven Meuth (Düsseldorf)

News

Mon, 20/09/2021
Register now: 1st Symposium inflammation and imaging
When?: from November 2nd to November 4th 2021 Where?: Schloss (seat of the University Administration) Muenster Organizers: Co-operative Research Centres 1009, 1450, Transregio 128, and Clinical Research Unit 342 – together with Interdisciplinary Centre of Clinical Research (IZKF) and Excellence Cluster Cells in Motion (CiM) Registration is open now! More information: here...more
Mon, 09/08/2021
Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity
A close interaction between gut immune responses and distant organ-specific autoimmunity including the CNS in multiple sclerosis has been established in recent years. This so-called gut-CNS axis can be shaped by dietary factors, either directly or via indirect modulation of the gut microbiome and its metabolites. Here, SFB 128 PI Luisa Klotz and colleagues report […]...more
Thu, 28/01/2021
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced the publication of preclinical data on its novel mRNA vaccine approach against autoimmune diseases in the peer-reviewed journal Science. The publication titled “A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis” co-authored by SFB principal investigator Ari Waisman summarizes the findings on the disease-suppressing effects […]...more